In this Q&A from Advisory Board, IPD Analytics' experts discussed what providers need to know about the U.S. biosimilar market.

Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth

IPD Analytics and ICER are collaborating to enhance drug pricing transparency.